Compass Therapeutics Inc. (CMPX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.79 (+4.01% 1D, market cap $136.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CMPX ranks #381 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and MOLN (Molecular Partners AG) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $0 in revenue, -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CMPX currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($0.83) forces dealer call-delta covering toward $7.22.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Compass Therapeutics Inc. (CMPX) surged +4.01% to $0.79, trading at 2% of its 52-week range ($0.73 – $6.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or de
Investing.com -- Emergent Biosolutions Inc (NYSE:EBS) shares dropped 1292% Friday after the company announced that Chief Financial Officer Richard Lindahl will retire at the end of 2026.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMPX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMPX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Compass Therapeutics Inc. (CMPX) ranks #381 by composite RQD confidence (46/100, grade D) and #620 by equity capitalization ($136.2M). Within this direct 5-issuer industry benchmark cohort, CMPX leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CMPX at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMPX
ACTIVE
Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | +4.01% | $136.2M | Benchmark Subject |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -7.60% | $138.8M | /chrs-vs-cmpx → |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | +1.42% | $132.4M | /moln-vs-cmpx → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | -5.13% | $141.2M | /crdl-vs-cmpx → |
| HUMA Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -12.47% | $130.5M | /huma-vs-cmpx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compass Therapeutics Inc. (CMPX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$66.5M, operating cash flow of -$49.1M, and free cash flow of -$49.2M (-9.5% YoY). On the balance sheet, CMPX closed FY2025 with $219.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$66.5M | -$49.1M | -$49.2M | $219.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$49.4M | -$44.9M | -$44.9M | $140.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$42.5M | -$40.6M | -$40.6M | — | — |
As of 2026-11-02, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.79 (+4.01% 1D, market cap $136.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CMPX ranks #381 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and MOLN (Molecular Partners AG) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $0 in revenue, -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CMPX last traded at $0.79 (+4.01% on volume of 2,918,281 shares), positioning the stock -45.89% below its 50-day simple moving average ($1.46) and -75.24% below its 200-day simple moving average ($3.19). Across its 52-week range of $0.73 to $6.88, CMPX sits at the 1.0% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).
Why CMPX Stock surged +4.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CMPX scores 46 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the Fundamental Cash Engine scores 8/20 (ROIC -34.6%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 13/20, reflecting institutional accumulation and options positioning, the strongest pillar in the set. Insider Conviction scores 5/20, based on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar. Macro Regime Fit scores 10/20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor evaluating the stock today, these scores point to a company with negative operating economics and weak insider signaling, partly offset by institutional interest. Upside drivers are limited to the institutional accumulation signal and any future progress that the source data does not describe. Valuation tradeoffs are difficult to frame because trailing and forward earnings multiples are Not available in source data; the market capitalization of $136.2M is the only valuation anchor provided. Second-order risks include balance sheet strain as operating losses persist, reflected in the reported cash decline across periods.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-72.8M | $-66.5M | N/A | $-49.2M | $30.6M | N/A |
| FY 2024 | $0.0M | $-56.6M | $-49.4M | N/A | $-44.9M | $43.5M | N/A |
| FY 2023 | $0.0M | $-50.4M | $-42.5M | N/A | $-40.6M | N/A | N/A |
Per the SEC financials, operating losses widened from $-50.4M (FY 2023) to $-72.8M (FY 2025), and reported cash fell from $43.5M (FY 2024) to $30.6M (FY 2025). Gross, operating, and net margins are each recorded as 0%, and ROIC is -34.6%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. The source data does not provide the debt amount, so the basis for the Debt/Equity figure cannot be verified within this dossier.
Per the news wire, the most prominent item is a Yahoo Finance report titled "Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns," flagged RED with a RISK WATCH impact label. Other items, including TradingView, StockInvest.us, debelegger.nl, Simply Wall St, and Stock Titan coverage, are flagged YELLOW with MARKET WIRE labels. One Stock Titan item notes that investors can request one-on-one meetings with Compass management at two November conferences. The news items are summaries of market action and do not contain independently verified fundamental detail. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.
Real-time company headlines, analyst actions, and sector developments for Compass Therapeutics Inc. (CMPX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Compass Therapeutics Inc. (CMPX) market action, institutional positioning, and fundamental catalysts.
Welcome to the CMPX (Compass Therapeutics Inc.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CMPX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Compass Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CMPX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.79 (52-wk range $0.73 - $6.88), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).